VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Becton, Dickinson and Company vs Novo Nordisk A/S
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Becton, Dickinson and Company
BDX · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Becton, Dickinson and Company's moat claims, evidence, and risks.
View BDX analysisNovo Nordisk A/S
NOVOB · Nasdaq Copenhagen
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.
View NOVOB analysisComparison highlights
- Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 66 / 100 for Becton, Dickinson and Company).
- Segment focus: Becton, Dickinson and Company has 5 segments (29.5% in Medical Essentials); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Weak vs Moderate.
- Moat breadth: Becton, Dickinson and Company has 7 moat types across 3 domains; Novo Nordisk A/S has 5 across 3.
Primary market context
Becton, Dickinson and Company
Medical Essentials
Single-use medical consumables and specimen collection systems
Global
Healthcare providers and clinical labs
Manufacturer
29.5%
Novo Nordisk A/S
Diabetes care
Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)
Global
Payers/providers and patients (via wholesalers/pharmacies/hospitals)
Originator pharma (R&D, regulatory, manufacturing, commercialization)
71.1%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Becton, Dickinson and Company strengths
Novo Nordisk A/S strengths
Segment mix
Becton, Dickinson and Company segments
Full profile >Medical Essentials
Competitive
Connected Care
Oligopoly
BioPharma Systems
Oligopoly
Interventional
Competitive
Life Sciences
Oligopoly
Novo Nordisk A/S segments
Full profile >Diabetes care
Oligopoly
Obesity care
Duopoly
Rare disease
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.